ATE493400T1 - Pyridin- und pyrimidinderivate als mglur2- antagonisten - Google Patents
Pyridin- und pyrimidinderivate als mglur2- antagonistenInfo
- Publication number
- ATE493400T1 ATE493400T1 AT08718155T AT08718155T ATE493400T1 AT E493400 T1 ATE493400 T1 AT E493400T1 AT 08718155 T AT08718155 T AT 08718155T AT 08718155 T AT08718155 T AT 08718155T AT E493400 T1 ATE493400 T1 AT E493400T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridine
- pyrimidine derivatives
- mglur2 antagonists
- mglur2
- antagonists
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105429 | 2007-04-02 | ||
| PCT/EP2008/053460 WO2008119689A1 (en) | 2007-04-02 | 2008-03-25 | Pyridine and pyrimidine derivatives as mglur2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493400T1 true ATE493400T1 (de) | 2011-01-15 |
Family
ID=39457413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08718155T ATE493400T1 (de) | 2007-04-02 | 2008-03-25 | Pyridin- und pyrimidinderivate als mglur2- antagonisten |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8012986B2 (de) |
| EP (1) | EP2142527B1 (de) |
| JP (1) | JP5303544B2 (de) |
| KR (1) | KR101143152B1 (de) |
| CN (1) | CN101641346B (de) |
| AR (1) | AR065891A1 (de) |
| AT (1) | ATE493400T1 (de) |
| AU (1) | AU2008233956B2 (de) |
| BR (1) | BRPI0809971A2 (de) |
| CA (1) | CA2681733A1 (de) |
| CL (1) | CL2008000936A1 (de) |
| DE (1) | DE602008004236D1 (de) |
| IL (1) | IL200780A (de) |
| MX (1) | MX2009010505A (de) |
| PE (1) | PE20090103A1 (de) |
| TW (1) | TW200845999A (de) |
| WO (1) | WO2008119689A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
| WO2012020820A1 (ja) | 2010-08-11 | 2012-02-16 | 大正製薬株式会社 | ヘテロアリール－ピラゾール誘導体 |
| JP2014062047A (ja) * | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
| EP2758379B1 (de) * | 2011-09-21 | 2016-10-19 | Cellzome Limited | Harnstoff- und Carbamatderivate des 2-Morpholino-1,3,5-Triazins als mTOR Inhibitoren zur Behandlung von immunologischen oder proliferative Erkrankungen |
| US10189825B2 (en) * | 2012-02-08 | 2019-01-29 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| KR20150070187A (ko) | 2012-10-23 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제 |
| KR20160143853A (ko) | 2014-04-23 | 2016-12-14 | 에프. 호프만-라 로슈 아게 | 지적 장애의 치료를 위한 mglu2/3 길항제 |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| AU2017301769B2 (en) | 2016-07-29 | 2022-07-28 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| CN112334457A (zh) * | 2018-06-22 | 2021-02-05 | 拜耳公司 | 制备三环化合物的方法 |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100838447B1 (ko) | 2001-02-21 | 2008-06-16 | 아스트라제네카 아베 | 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도 |
| AU2004228057A1 (en) * | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| WO2004089308A2 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| EP1683804B1 (de) * | 2003-11-04 | 2013-07-31 | Takasago International Corporation | Platinkomplex und lumineszentes element |
| US20060173048A1 (en) | 2005-02-03 | 2006-08-03 | Mcarthur Silvia G | Imidazole derivatives |
| CA2646732C (en) | 2006-03-29 | 2015-04-28 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
| US20070236568A1 (en) | 2006-04-11 | 2007-10-11 | Metke Anthony R | Method and system for communicating incident scene information |
-
2008
- 2008-03-24 US US12/053,648 patent/US8012986B2/en not_active Expired - Fee Related
- 2008-03-25 AU AU2008233956A patent/AU2008233956B2/en not_active Ceased
- 2008-03-25 DE DE602008004236T patent/DE602008004236D1/de active Active
- 2008-03-25 WO PCT/EP2008/053460 patent/WO2008119689A1/en not_active Ceased
- 2008-03-25 KR KR1020097020481A patent/KR101143152B1/ko not_active Expired - Fee Related
- 2008-03-25 MX MX2009010505A patent/MX2009010505A/es active IP Right Grant
- 2008-03-25 EP EP08718155A patent/EP2142527B1/de not_active Not-in-force
- 2008-03-25 CN CN2008800096420A patent/CN101641346B/zh not_active Expired - Fee Related
- 2008-03-25 AT AT08718155T patent/ATE493400T1/de active
- 2008-03-25 JP JP2010501476A patent/JP5303544B2/ja not_active Expired - Fee Related
- 2008-03-25 BR BRPI0809971-5A2A patent/BRPI0809971A2/pt not_active IP Right Cessation
- 2008-03-25 CA CA002681733A patent/CA2681733A1/en not_active Abandoned
- 2008-03-31 AR ARP080101333A patent/AR065891A1/es unknown
- 2008-03-31 TW TW097111725A patent/TW200845999A/zh unknown
- 2008-04-01 PE PE2008000591A patent/PE20090103A1/es not_active Application Discontinuation
- 2008-04-01 CL CL200800936A patent/CL2008000936A1/es unknown
-
2009
- 2009-09-07 IL IL200780A patent/IL200780A/en not_active IP Right Cessation
-
2011
- 2011-07-08 US US13/178,531 patent/US8415380B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2681733A1 (en) | 2008-10-09 |
| IL200780A (en) | 2013-01-31 |
| EP2142527B1 (de) | 2010-12-29 |
| AU2008233956B2 (en) | 2013-05-02 |
| CL2008000936A1 (es) | 2008-10-03 |
| MX2009010505A (es) | 2009-10-19 |
| AR065891A1 (es) | 2009-07-08 |
| EP2142527A1 (de) | 2010-01-13 |
| KR101143152B1 (ko) | 2012-05-08 |
| CN101641346B (zh) | 2013-11-06 |
| DE602008004236D1 (de) | 2011-02-10 |
| US20110263615A1 (en) | 2011-10-27 |
| JP2010524852A (ja) | 2010-07-22 |
| AU2008233956A1 (en) | 2008-10-09 |
| CN101641346A (zh) | 2010-02-03 |
| PE20090103A1 (es) | 2009-02-13 |
| BRPI0809971A2 (pt) | 2014-10-07 |
| WO2008119689A1 (en) | 2008-10-09 |
| TW200845999A (en) | 2008-12-01 |
| KR20090117902A (ko) | 2009-11-13 |
| US8012986B2 (en) | 2011-09-06 |
| IL200780A0 (en) | 2010-05-17 |
| JP5303544B2 (ja) | 2013-10-02 |
| US20080280924A1 (en) | 2008-11-13 |
| US8415380B2 (en) | 2013-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE493400T1 (de) | Pyridin- und pyrimidinderivate als mglur2- antagonisten | |
| ZA200808191B (en) | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | |
| BRPI0810202A2 (pt) | Derivados de piridina | |
| BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| ES2465673T9 (es) | Derivados de pirimidina | |
| BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
| BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| DK2046740T3 (da) | Forbindelser med CRTH2-antagonistisk virkning | |
| ATE478064T1 (de) | Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate | |
| ATE486063T1 (de) | 2-substituierte 4-benzylphthalazinonderivate als histamin-h1- und h3-antagonisten | |
| ATE460417T1 (de) | Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten | |
| ATE481409T1 (de) | Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor | |
| BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
| EP2234486A4 (de) | Benzimidazole und analoge als rho-kinasehemmer | |
| HRP20190016T1 (hr) | Heterociklički spojevi i njihova upotreba | |
| ATE546433T1 (de) | Quinolinderivate und ihre verwendung als fungizide | |
| BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
| ATE512966T1 (de) | Pyrazolo-pyrimidin-derivate als mglur2- antagonisten | |
| SI2188291T1 (sl) | Zliti biciklični pirimidini | |
| BRPI0817835A2 (pt) | Antagonistas cgrp | |
| ATE478059T1 (de) | Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten | |
| ATE537149T1 (de) | Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten | |
| BRPI0811115A2 (pt) | Compostos de heteroarilamida pirimidona | |
| BRPI0820779A2 (pt) | Derivados de 4-amino-pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2142527 Country of ref document: EP |